GENOTYPE SPECIFIC THERAPY: FOCUS ON LQT3

Wednesday 25 October | 15.45-17.15

 
Core Curriculum
GENOTYPE SPECIFIC THERAPY: FOCUS ON LQT3

 
Chairs: C. Antzelevitch / Wynnewood, USA –
S.G. Priori / Pavia, Italy

 
Beta-blockers: contraindicated or treatment of choice for LQT3
A.A. Wilde / Amsterdam, The Netherlands
Flecainide for LQT3
E. Chorin / Tel Aviv, Israel
• Mexiletine for LQT3
A. Mazzanti / Pavia, Italy
• Ranolazine for LQT3
R. Rosso / Tel Aviv, Israel